Abstract
Introduction: We conducted a single-arm, open-label dose-exploration study to evaluate the safety and efficacy of the histone deacetylase inhibitor tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone (C-PDD) in treating relapsed and refractory multiple myeloma (RRMM) patients. Methods: Eighteen patients were enrolled from August 2020 to May 2021, receiving 21-day cycles of C-PDD. Results: Eighteen cases were analysed, with a median prior treatment line of 2 (range: 1–4). The median number of completed treatment cycles was 4 (range: 1–8). The overall response rate was 57%, including 14% complete response, 14% very good partial response, and 29% partial response. Both bortezomib-sensitive and refractory groups had a response rate of 57%. The response rate was 100% in patients with extramedullary extraosseous involvement. The median follow-up was 42 months (range: 3–44), with median progression-free survival of 7 months and median overall survival of 24.5 months. Grade 3–4 haematologic adverse events included thrombocytopaenia (50%), neutropenia (33%), and anaemia (33%). Non-haematologic adverse events were mostly grade 1–2, with 1 case of grade 3 peripheral sensory neuropathy. Conclusion: The C-PDD regimen showed efficacy in RRMM, including bortezomib-refractory disease and EME patients. The optimal dose and combination need to be explored in the future.
References
1.
Wang
S
, Xu
L
, Feng
J
, Liu
Y
, Liu
L
, Wang
J
, et al. Prevalence and incidence of multiple myeloma in urban area in China: a national population-based analysis
. Front Oncol
. 2019
;9
:1513
. 2.
Liu
W
, Liu
J
, Song
Y
, Wang
X
, Zhou
M
, Wang
L
, et al. Mortality of lymphoma and myeloma in China, 2004-2017: an observational study
. J Hematol Oncol
. 2019
;12
(1
):22
. 3.
Lu
J
, Lu
J
, Chen
W
, Huo
Y
, Huang
X
, Hou
J
, et al. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis
. Blood Cancer J
. 2014
;4
(8
):e239
. 4.
Kumar
SK
, Lee
JH
, Lahuerta
JJ
, Morgan
G
, Richardson
PG
, Crowley
J
, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
. Leukemia
. 2012
;26
(1
):149
–57
. 5.
Lecat
CSY
, Taube
JB
, Wilson
W
, Carmichael
J
, Parrish
C
, Wallis
G
, et al. Defining unmet need following lenalidomide refractoriness: real-world evidence of outcomes in patients with multiple myeloma
. Front Oncol
. 2021
;11
:703233
. 6.
Ohguchi
H
, Hideshima
T
, Anderson
KC
. The biological significance of histone modifiers in multiple myeloma: clinical applications
. Blood Cancer J
. 2018
;8
(9
):83
. 7.
Mithraprabhu
S
, Kalff
A
, Chow
A
, Khong
T
, Spencer
A
. Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
. Epigenetics
. 2014
;9
(11
):1511
–20
. 8.
Carew
JS
, Giles
FJ
, Nawrocki
ST
. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy
. Cancer Lett
. 2008
;269
(1
):7
–17
. 9.
Mitsiades
CS
, Mitsiades
NS
, McMullan
CJ
, Poulaki
V
, Shringarpure
R
, Hideshima
T
, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications
. Proc Natl Acad Sci U S A
. 2004
;101
(2
):540
–5
. 10.
Orlowski
RZ
, Nagler
A
, Sonneveld
P
, Bladé
J
, Hajek
R
, Spencer
A
, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression
. J Clin Oncol
. 2007
;25
(25
):3892
–901
. 11.
Mitsiades
N
, Mitsiades
CS
, Richardson
PG
, Poulaki
V
, Tai
Y-T
, Chauhan
D
, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
. Blood
. 2003
;101
(6
):2377
–80
. 12.
Orlowski
RZ
, Stinchcombe
TE
, Mitchell
BS
, Shea
TC
, Baldwin
AS
, Stahl
S
, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
. J Clin Oncol
. 2002
;20
(22
):4420
–7
. 13.
Voorhees
PM
, Gasparetto
C
, Moore
DT
, Winans
D
, Orlowski
RZ
, Hurd
DD
. Final results of a phase 1 study of vorinostat, pegylated liposomal doxorubicin, and bortezomib in relapsed or refractory multiple myeloma
. Clin Lymphoma Myeloma Leuk
. 2017
;17
(7
):424
–32
. 14.
Bondarev
AD
, Attwood
MM
, Jonsson
J
, Chubarev
VN
, Tarasov
VV
, Schiöth
HB
. Recent developments of HDAC inhibitors: emerging indications and novel molecules
. Br J Clin Pharmacol
. 2021
;87
(12
):4577
–97
. 15.
Pan
D-S
, Yang
Q-J
, Fu
X
, Shan
S
, Zhu
J-Z
, Zhang
K
, et al. Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment
. MedChemComm
. 2014
;5
(12
):1789
–96
. 16.
Zhao
W
, Zhu
J
, Song
Y
, Xu
P-P
, Shen
J
, Cai
Q
, et al. Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: an interim analysis from the phase III DEB study
. J Clin Orthod
. 2024
;42
(17_Suppl l
):LBA7003-LBA7003
. 17.
Zhang
H
, Dong
L
, Chen
Q
, Kong
L
, Meng
B
, Wang
H
, et al. Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma
. Leuk Res
. 2017
;56
:29
–35
. 18.
He
J
, Chen
Q
, Gu
H
, Chen
J
, Zhang
E
, Guo
X
, et al. Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease
. Haematologica
. 2018
;103
(8
):1369
–79
. 19.
Xu
L
, Feng
J
, Tang
H
, Dong
Y
, Shu
M
, Chen
X
. Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib
. Cell Death Dis
. 2020
;11
(4
):297
. 20.
Dong
M
, Ning
Z-Q
, Xing
P-Y
, Xu
J-L
, Cao
H-X
, Dou
G-F
, et al. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas
. Cancer Chemother Pharmacol
. 2012
;69
(6
):1413
–22
. 21.
Shi
Y
, Dong
M
, Hong
X
, Zhang
W
, Feng
J
, Zhu
J
, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
. Ann Oncol
. 2015
;26
(8
):1766
–71
. 22.
Kumar
S
, Paiva
B
, Anderson
KC
, Durie
B
, Landgren
O
, Moreau
P
, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
. Lancet Oncol
. 2016
;17
(8
):e328
–46
. 23.
Hideshima
T
, Richardson
PG
, Anderson
KC
. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma
. Mol Cancer Ther
. 2011
;10
(11
):2034
–42
. 24.
Muchtar
E
, Gatt
ME
, Rouvio
O
, Ganzel
C
, Chubar
E
, Suriu
C
, et al. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study
. Br J Haematol
. 2016
;172
(1
):89
–96
. 25.
Short
KD
, Rajkumar
SV
, Larson
D
, Buadi
F
, Hayman
S
, Dispenzieri
A
, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma
. Leukemia
. 2011
;25
(6
):906
–8
. 26.
Waterman
GN
, Yellin
O
, Swift
RA
, Mapes
R
, Eades
B
, Ackerman
E
, et al. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma
. Ann Hematol
. 2011
;90
(2
):193
–200
. 27.
Romano
A
, Chiarenza
A
, Conticello
C
, Cavalli
M
, Vetro
C
, Di Raimondo
C
, et al. Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients
. Eur J Haematol
. 2014
;93
(3
):207
–13
. 28.
Berenson
JR
, Yellin
O
, Kazamel
T
, Hilger
JD
, Chen
CS
, Cartmell
A
, et al. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
. Leukemia
. 2012
;26
(7
):1675
–80
. 29.
Waldschmidt
JM
, Keller
A
, Ihorst
G
, Grishina
O
, Müller
S
, Wider
D
, et al. Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)
. Haematologica
. 2018
;103
(10
):e473
–9
. 30.
Richardson
PG
, Schlossman
RL
, Alsina
M
, Weber
DM
, Coutre
SE
, Gasparetto
C
, et al. Panorama 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
. Blood
. 2013
;122
(14
):2331
–7
. 31.
San-Miguel
JF
, Hungria
VTM
, Yoon
S-S
, Beksac
M
, Dimopoulos
MA
, Elghandour
A
, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
. Lancet Oncol
. 2014
;15
(11
):1195
–206
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
